Medications

Potential combined drug therapy for lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly ...

Genetics

Study reveals new insights into facial birth defects

Mount Sinai researchers have revealed new insights into how the body regulates craniofacial development in newborns, which can sometimes lead to birth defects such as cleft lip or palate.

Medications

Potential drug treatment for particular type of lung-cancer

The effectiveness of cancer treatment is often hampered by cancer cells being heterogeneous. This is the case for EGFR-mutated lung cancer: drugs based on biomolecules of a type known as tyrosine kinase inhibitor (TKI) have ...

Oncology & Cancer

Overcoming therapeutic resistance in lung cancer

A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery. In preclinical ...

Oncology & Cancer

Immune clues to help leukaemia patients safely stop treatment

Researchers with SAHMRI's Precision Medicine Theme have found a key to better identifying which chronic myeloid leukaemia (CML) patients can stop taking their medication and remain in treatment free remission (TFR).

page 4 from 26